<

ABSCIENCES (EPA:AB) AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib

Transparency directive : regulatory news

14/09/2021 18:01



Other stories

26/04/2024 00:26
25/04/2024 23:49
25/04/2024 20:31
25/04/2024 18:24
25/04/2024 17:33
25/04/2024 21:38
25/04/2024 23:04
25/04/2024 16:59
25/04/2024 22:37
25/04/2024 12:31
26/04/2024 00:01
25/04/2024 19:12
25/04/2024 18:42
25/04/2024 06:50
25/04/2024 18:59
25/04/2024 20:53
25/04/2024 17:29
25/04/2024 11:49
25/04/2024 22:55
26/04/2024 00:44
24/04/2024 09:00
24/04/2024 09:06
25/04/2024 18:23
25/04/2024 23:15
25/04/2024 20:32
26/04/2024 02:27
26/04/2024 01:00
26/04/2024 00:52
26/04/2024 00:30
25/04/2024 16:49
25/04/2024 21:00
25/04/2024 19:30
24/04/2024 07:30
25/04/2024 20:44
25/04/2024 15:13
26/04/2024 01:45
25/04/2024 06:00
24/04/2024 22:01